Utomilumab, previously known as PF-2566, represents a significant innovative avenue in autoimmune disorders. This monoclonal antibody uniquely inhibits the function of FcγRIIa – a key component https://1417318-27-4295029.activoblog.com/709755/utomilumab-a-thorough-examination-into-this-promise